Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker.
about
Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.Fibulin-3 as a biomarker of response to treatment in malignant mesotheliomaFibulin-4 promotes osteosarcoma invasion and metastasis by inducing epithelial to mesenchymal transition via the PI3K/Akt/mTOR pathway.Identification of 5 novel genes methylated in breast and other epithelial cancers.Gene profiling of MTA1 identifies novel gene targets and functions.Epigenetic heredity of human height.Anti-EGFR function of EFEMP1 in glioma cells and patient prognosis.Epigenetic inactivation of EFEMP1 is associated with tumor suppressive function in endometrial carcinoma.Overexpression of EFEMP1 correlates with tumor progression and poor prognosis in human ovarian carcinomaFibulin-4 is associated with tumor progression and a poor prognosis in ovarian carcinomasThe identification of specific methylation patterns across different cancersEFEMP1 suppresses malignant glioma growth and exerts its action within the tumor extracellular compartment.Global transcriptomic analysis of model human cell lines exposed to surface-modified gold nanoparticles: the effect of surface chemistry.A seven-gene CpG-island methylation panel predicts breast cancer progressionMitochondrial DNA variants can mediate methylation status of inflammation, angiogenesis and signaling genes.EFEMP1 promotes the migration and invasion of osteosarcoma via MMP-2 with induction by AEG-1 via NF-κB signaling pathway.Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis.Fibulin-3 is a novel TGF-β pathway inhibitor in the breast cancer microenvironment.Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.Secreted proteins as a fundamental source for biomarker discovery.Cell context-dependent dual effects of EFEMP1 stabilizes subpopulation equilibrium in responding to changes of in vivo growth environmentEpidermal growth factor-containing fibulin-like extracellular matrix protein 1 expression and regulation in uterine leiomyoma.Expansion of epigenetic alterations in EFEMP1 promoter predicts malignant formation in pancreatobiliary intraductal papillary mucinous neoplasmsDecrease of fibulin-3 in hepatocellular carcinoma indicates poor prognosis.Exosome-mediated delivery of miR-9 induces cancer-associated fibroblast-like properties in human breast fibroblasts.Reduced expressions of connexin 43 and VEGF in the first-trimester tissues from women with recurrent pregnancy loss.EFEMP1 is repressed by estrogen and inhibits the epithelial-mesenchymal transition via Wnt/β-catenin signaling in endometrial carcinoma.Weaponizing human EGF-containing fibulin-like extracellular matrix protein 1 (EFEMP1) for 21st century cancer therapeutics.Proteomic analysis of human aqueous humor using multidimensional protein identification technology.EFEMP1 promotes ovarian cancer cell growth, invasion and metastasis via activated the AKT pathway.Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions.Emerging biomarkers in breast cancer care.Epidermal Growth Factor-Containing Fibulin-Like Extracellular Matrix Protein 1 (EFEMP1) Acts as a Potential Diagnostic Biomarker for Prostate CancerEpigenetic regulation of EFEMP1 in prostate cancer: biological relevance and clinical potential.Integrative DNA methylation and gene expression analysis in high-grade soft tissue sarcomasp38 MAPK down-regulates fibulin 3 expression through methylation of gene regulatory sequences: role in migration and invasion.Fibulin-3 promotes muscle-invasive bladder cancer.Plasma Fibulin-3 as a Potential Biomarker for Patients with Asbestos-Related Diseases in the Han Population.Biomedical application of fuzzy association rules for identifying breast cancer biomarkers.Tumour-microenvironment interactions: role of tumour stroma and proteins produced by cancer-associated fibroblasts in chemotherapy response.
P2860
Q24628879-4EE462FC-193A-4B78-9BB1-3C49E123D245Q28389185-49DEBE8C-CD42-484B-A457-2534BB08A7CFQ33598331-5B1A067A-AE97-43FE-A490-3E63C3A1AB54Q33737079-115EDC06-1093-4207-9717-D7F1B068F7F6Q33833747-30B2E551-A15B-43A8-9713-B03F70DE4755Q34399991-D134818B-8923-46E6-9123-3CDF2FE0D095Q34781171-96576F93-91BB-48F4-9A26-3B0D113D8F7BQ34807396-0148B3EB-867F-46ED-8E66-851FEC67B305Q35043581-6F883474-C48A-48A1-B87A-CF489B96AEECQ35177014-FB033717-0550-46F4-B6FF-C56189C38369Q35182046-73335A8E-943C-41F5-B086-61F7314AE154Q35478122-149F0CB6-E310-437C-A667-CF7FDA7C7B18Q35545338-BD71F5F4-8686-4435-AF7E-D06D967586CAQ35626799-49E36DCC-B59C-4060-93AB-9121D0D8B6D9Q35882554-363B14B7-5D56-4F29-A0D5-528609B47316Q35987298-7D05F140-E3CE-47BC-B5DE-1AF7F887F70EQ36081391-4DF8CB1E-4D81-494F-BBC7-3AA2CC64F1E1Q36108833-42A0E7EF-F792-49AA-8C02-06225EE084C0Q36166929-3F23785F-F83A-4683-B137-5B7439D08E1CQ36452973-F079DA3C-4040-4793-A593-9123D1698184Q36544417-D26E8958-27C4-4442-8315-34BD6F3CEA50Q36794310-019A2288-91D3-45A8-88F4-57B3C3F8FC9EQ36985263-6A958306-1D75-4DE6-AB11-978B34CD5C05Q37064102-B7D368A0-66A3-4A58-8AC2-238CDD2FCDB9Q37151539-176A1C5B-5B8B-4F96-A181-2F12B80BC3BCQ37185222-CBC24993-F33B-4AEF-BE0F-E596B7AF692DQ37295470-8E327383-3D52-465B-921A-26513A64591EQ37298184-3A46D826-C142-4F6F-ACF1-F650F5BD959EQ37476824-A56D3403-2176-4E98-B506-AF05A0ACF0A5Q37565332-749E0DEA-2326-4419-A110-26A8B07081F5Q37580229-97DDCED4-65B6-4977-B418-667287F105CBQ37779305-17316FD2-266E-4AB3-923E-CA3F62201C6CQ38721452-5F3C2347-3950-42A6-95D9-51137DC2BCEBQ38957460-27B51680-1172-458C-AA7D-5C5E3168BFA0Q39042581-5CEFE295-8C1D-4BF9-822B-F6F8151D53D5Q42126197-F3F9E1FF-A6A9-41CF-9538-5E56999F0171Q42776532-7DC30E51-ED89-4A4D-B8A9-2281473AA0ABQ45824718-F46CEDB7-9437-40A6-A496-41FE052EA417Q46736635-1F96524F-841E-40DE-9288-E56A63501091Q52841791-A4A949D3-EEA9-4B90-B0EF-2501B406B870
P2860
Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Decreased expression of angiog ...... EFEMP1 as molecular biomarker.
@en
Decreased expression of angiog ...... EFEMP1 as molecular biomarker.
@nl
type
label
Decreased expression of angiog ...... EFEMP1 as molecular biomarker.
@en
Decreased expression of angiog ...... EFEMP1 as molecular biomarker.
@nl
prefLabel
Decreased expression of angiog ...... EFEMP1 as molecular biomarker.
@en
Decreased expression of angiog ...... EFEMP1 as molecular biomarker.
@nl
P2093
P50
P356
P1476
Decreased expression of angiog ...... EFEMP1 as molecular biomarker.
@en
P2093
Ariane Sadr-Nabavi
Beate Betz
Dieter Niederacher
Edgar Dahl
Frank Wiesmann
Heide Hellebrand
Joerg Naehrig
Juliane Ramser
Juliane Volkmann
Marion Kiechle
P304
P356
10.1002/IJC.24108
P577
2009-04-01T00:00:00Z